Cognitive function · Apathy in people with mild‐to‐moderate Alzheimer's disease
2 findings from 1 review
Change in capacity for activities of daily living · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Physician rated global impression tests (no change or worse compared with baseline, measured using Global Impression of Change at 26 weeks) · Apathy in people with mild‐to‐moderate Alzheimer's disease
Rivastigmine probably leads to lower physician rated global impression tests (no change or worse compared… compared with placebo (moderate certainty).
1 finding from 1 review
Behavioural symptoms (change from baseline at 26 weeks measured using various scales) · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Acceptability · Apathy in people with mild‐to‐moderate Alzheimer's disease
Rivastigmine probably leads to higher acceptability of treatment (as measured by withdrawals from trials… compared with placebo (moderate certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · Apathy in people with mild‐to‐moderate Alzheimer's disease
Rivastigmine probably leads to higher incidence of adverse events (at least one adverse event by 26 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Quality of life of patients or carers (measured using NPI‐D carer distress scale (change from baseline at 24 weeks) · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Cognitive function · vascular dementia and other vascular cognitive impairments
1 finding from 1 review
Functional ability: independence with activities of daily living at discharge from hospital · vascular dementia and other vascular cognitive impairments
1 finding from 1 review
Adverse events (all adverse events) at 24 to 26 weeks · vascular dementia and other vascular cognitive impairments
It is very uncertain whether rivastigmine changes adverse events (all adverse events) at 24 to 26 weeks compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events (excluding death) at 24 to 26 weeks · vascular dementia and other vascular cognitive impairments
Rivastigmine showed no clear difference in serious adverse events (excluding death) at 24 to 26 weeks compared with placebo (low certainty).
1 finding from 1 review
Duration of delirium Days · people with delirium
1 finding from 1 review
Severity of delirium CAM negative · people with delirium
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: nausea · people with delirium
Cholinesterase inhibitors (rivastigmine) showed no clear difference in adverse events nausea compared with placebo (low certainty).
1 finding from 1 review
Persistent cognitive impairment · people with delirium
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · people with delirium
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people with delirium
Cholinesterase inhibitors (rivastigmine) showed no clear difference in mortality compared with placebo (low certainty).
1 finding from 1 review
Cost of the intervention · people with delirium
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found